Castle Creek Pharmaceuticals has announced the appointment of Mary Spellman as chief medical officer and senior vice president of research & development of Castle Creek.
Mary is a board‑certified dermatologist with over 30 years of clinical experience. Prior to joining Castle Creek, she managed the planning and execution of late-stage clinical programs as chief medical officer of Menlo Therapeutics and previously was a medical consultant providing medical and safety support for multiple biopharmaceutical and device development companies.
“We are pleased to welcome Dr. Spellman to the Castle Creek team as we advance into late stage clinical development with our investigational diacerein ointment for the potential treatment of patients with epidermolysis bullosa simplex,” said Greg Wujek, chief executive officer of Castle Creek. “Dr. Spellman brings decades of experience in the biopharmaceutical industry and has supported the successful development of topical products. We look forward to her insights, not only as a leader in our industry but also as an accomplished practicing dermatologist.”
